Ruth JnoBaptiste
Overview
Explore the profile of Ruth JnoBaptiste including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McNaught K, JnoBaptiste R, Jackson T, Jengelley T
Synapse
. 2009 Nov;
64(3):241-50.
PMID: 19924695
The basis of neuronal vulnerability, degeneration, and sparing in PD are unknown, but there is increasing evidence to suggest that the ubiquitin-proteasome system (UPS) plays an important role in the...
2.
McNaught K, Jackson T, JnoBaptiste R, Kapustin A, Olanow C
Neurology
. 2006 May;
66(10 Suppl 4):S37-49.
PMID: 16717251
The cause and mechanism of neuronal death in sporadic Parkinson's disease (PD) continue to elude investigators. Recently, alterations in proteasomal function have been detected in the brain of patients with...
3.
McNaught K, Kapustin A, Jackson T, Jengelley T, JnoBaptiste R, Shashidharan P, et al.
Ann Neurol
. 2004 Sep;
56(4):540-7.
PMID: 15455404
DYT1 dystonia is a severe form of young-onset dystonia caused by a mutation in the gene that encodes for the protein torsinA, which is thought to play a role in...
4.
Kramer B, Yabut J, Cheong J, JnoBaptiste R, Robakis T, Olanow C, et al.
Eur J Neurosci
. 2004 Jan;
19(2):280-6.
PMID: 14725622
The contribution of arachidonic acid (AA) release and metabolism to the toxicity that results from glutathione (GSH) depletion was studied in rat mesencephalic cultures treated with the GSH synthesis inhibitor...
5.
Mytilineou C, Walker R, JnoBaptiste R, Olanow C
J Pharmacol Exp Ther
. 2003 Jan;
304(2):792-800.
PMID: 12538835
Levodopa is the "gold standard" for the symptomatic treatment of Parkinson's disease (PD). There is a theoretical concern, however, that levodopa might accelerate the rate of nigral degeneration, because it...
6.
McNaught K, Mytilineou C, JnoBaptiste R, Yabut J, Shashidharan P, Jennert P, et al.
J Neurochem
. 2002 Jun;
81(2):301-6.
PMID: 12064477
Mutations in alpha-synuclein, parkin and ubiquitin C-terminal hydrolase L1, and defects in 26/20S proteasomes, cause or are associated with the development of familial and sporadic Parkinson's disease (PD). This suggests...